adequate glycemic control both short- and long-term prevention of acute episodes of hyperglycemia and hypoglycemia tolerability, treatment tolerance, and impact on QOL longer-term reduction of microvascular and macrovascular complications; improvement in QOL and survival.
56, 57 This reduction increases treatment tolerance and decreases local irritation, although local irritation has been described as well tolerated since the first cases 50, 51 and there are cases of good results with application to the eyelid and penis.
Malnutrition in oncology patients is associated with poorer treatment tolerance, poorer outcomes and a poorer quality of life.
Furthermore, the reduced treatment tolerance of post-gastrectomy patients, perhaps due to their poor nutritional status, results in decreased or delayed adjuvant systemic therapy, with potential adverse consequences in its efficacy.
This study was conducted to examine the psychometric properties of 5 brief OAB measures: International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), Subject's Assessment of Condition (SAC), Subject's Assessment of Treatment Satisfaction (SATS), Subject's Assessment of Treatment Tolerance (SATT), and Treatment Benefit Scale (TBS).
In this study, we aimed to use a questionnaire covering all the relevant symptomatic toxicities for a specific cancer treatment, which is important in order to use the patient's reporting in the discussion of treatment tolerance and supportive care with the oncologist.
Treatment tolerance was good.
Some are justified by patient comorbidity and reduced treatment tolerance.
Treatment tolerance has been addressed in some studies [ 6, 7].
Treatment tolerance with combined modality is good in elderly patients.
No differences in treatment tolerance were observed between the MS and MMF groups.
